Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

3SBIO INC Ord Shs TRSBF

3SBio Inc. is an investment holding company mainly engaged in the the development, production, marketing and sale of pharmaceutical products. The Company’s main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)ainhibitor products and recombinant human erythropoietin (rhEPO) products. The products are sold under the name of TPIAO, Yisaipu, EPIAO and SEPO. The Company distributes its products within the domestic market and to overseas markets, including Sri Lanka, Dominican Republic and Thailand. The Company’s subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd.. Through its subsidiaries, the Company is engaged in project management and consultation.


OTCPK:TRSBF - Post by User

Post by theinvestor22on Nov 03, 2008 10:24am
636 Views
Post# 15562193

Ah, enlightenment

Ah, enlightenmentAfter listening to the Q3 08 preliminary earnings conference call, I can see I need to update my posting of yesterday, specifically:

- Per share earnings were better than I estimated they'd be, given that the $2.7M write-off isn't tax deductible.  Q3 eps should be something in the order of $.14/share.

- The cash flow amount of $6.4M is for Q1-Q3, not just for Q3 alone.  That makes sense. (my mistake)

- The plant now under construction should use up about $20M of capital to complete, which will leave about $79.5M of cash + $8.6M of securities + future cash flow available for share buybacks, expansion and acquisitions.  Just the cash and securities total $88.1M or $4.05/share.  That's a lot of resources in addition to a sizeable new production facility.

It is interesting to note that, at the conference call, three callers admonished the company for not buying back any shares to date.  I agree with these callers; it doesn't matter if the company purchases its own shares at the absolute low price, any price in the current range will do.  The stock is dirt cheap right now.  After all, they would be buying back shares at say $6.50 that they sold to the public last year at $16.00.

<< Previous
Bullboard Posts
Next >>